Selecting a site will automatically redirect you to the site's homepage.
A Cornell-led collaboration devised a potentially low-cost method for producing antibodies for therapeutic treatments: bioengineered bacteria with an overlooked enzyme that can help monoclonal antibodies boost their immune defenses.
Cornell scientists work toward engineering plants and other organisms to grow into usable, biodegradable forms.
